Clinical Study of Chemotherapy-Enteral Nutrition Based Therapy Combined with Programmed Death-1 Inhibitor in the Treatment of Patients with Hepatocellular Carcinoma
Objective:To investigate the therapeutic effect of chemotherapy-enteral nutrition based therapy combined with programmed death-1(PD-1)inhibitor in patients with hepatocellular carcinoma.Methods:A Total of 78 patients with hepatocellular carcinoma admitted to a hospital from January 2020 to December 2022 were retrospectively selected and divided into the control group(n=42)and the observation group(n=36)according to the treatment regimens recorded in the medical record system.Patients in the control group were treated with transcatheter arterial chemoembolization(TACE)and enteral nutrition,while patients in the observation group were treated with PD-1 inhibitor pembrolizumab injection in addition to the treatment of the control group.The clinical efficacy,liver function[alanine aminotransferase(ALT),aspartate aminotransferase(AST),indirect bilirubin(IBIL)and direct bilirubin(DBIL)],immune function[CD3+,CD4+,CD8+and CD4+/CD8+]and the incidence of adverse reactions were compared between the two groups.Results:After 3 weeks of treatment and 6 weeks of treatment,the disease control rate in the observation group was higher than that of control group(P<0.05).Serum ALT,AST,IBIL and DBIL levels and CD8+were decreased in both groups,and the observation group were lower than those in the control group(P<0.05).CD3+,CD4+and CD4+/CD8+were increased in both groups,and the observation group were higher than those in the control group(P<0.05).Repeated-measures ANOVA showed statistically significant differences in between-group effects,time effects,and interaction effects for serum ALT,AST,IBIL and DBIL levels,and peripheral blood CD3+,CD4+,CD8+,and CD4+/CD8+between the two groups(P<0.05).During the treatment period,there was no statistically significant difference was observed in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Chemotherapy-enteral nutrition based therapy in combination with PD-1 demonstrated favorable clinical efficacy and can improve the liver function and immune function of hepatocellular carcinoma patients,and does not elevate the risk of adverse reactions.
chemotherapyenteral nutritionprogrammed death-1 inhibitorhepatocellular carcinomaliver functionimmune function
万方数据
维普
